LentiArray™ Cas9 Lentivirus
Product Image
Invitrogen™

LentiArray™ Cas9 Lentivirus

Have Questions?
產品號碼Quantity
A32064100 μL
產品號碼 A32064
價格 (HKD)
6,377.00
Each
新增至購物車
Quantity:
100 μL
價格 (HKD)
6,377.00
Each
新增至購物車

LentiArray Cas9 Lentivirus provides an efficient method to drive high level Cas9 nuclease expression in a wide variety of cell types. The LentiArray Cas9 Lentivirus construct includes a human codon-optimized version of Cas9 with two nuclear localization signals to facilitate efficient delivery into the nucleus. The 100 μL size is sufficient for creating stable Cas9 expressing pools of cells or for isolating stable Cas9 expressing clones. LentiArray Cas9 Lentivirus is provided as ready to use lentivirus at a titer of 1 x 107 TU/mL.

For Research Use Only. Not for use in diagnostic procedures.
規格
Delivery TypeLentiviral
For Use With (Application)CRISPR gene knockout
Product LineLentiArray
Product TypeCas9 Lentivirus
Quantity100 μL
Shipping ConditionDry Ice
PromoterEF-1a
Sample TypegRNA
SpeciesHuman
Transfection TechniqueLentiviral transduction
Unit SizeEach
內容物與存放
1 x 100 μL. Store at -68 to -85°C.

引用資料與參考文獻 (1)

引用資料與參考文獻
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More